Phosphodiesterase type 5 inhibitor (PDE5 inhibitor) is a drug used to block degradation of cgmp-specific phosphodiesterase type 5 (PDE5) loop GMP in smooth muscle cell lining supplying blood vessels to various tissues.These drugs dilate the cavernous penis, promote erections with sexual stimulation, and are used to treat erectile dysfunction (ED).Sildenafil is the first effective oral therapy for ED.Because PDE5 is also present in the wall of the smooth muscle arterioles of the inner lung, sildenafil and tadalafil dilate these vessels and are FDA approved for the treatment of pulmonary hypertension.

Market Analysis and Insights: Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market
The global Phosphodiesterase Type 5 (PDE5) Inhibitor market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Phosphodiesterase Type 5 (PDE5) Inhibitor market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Phosphodiesterase Type 5 (PDE5) Inhibitor market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Phosphodiesterase Type 5 (PDE5) Inhibitor market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Phosphodiesterase Type 5 (PDE5) Inhibitor market.

Global Phosphodiesterase Type 5 (PDE5) Inhibitor Scope and Market Size
Phosphodiesterase Type 5 (PDE5) Inhibitor market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Phosphodiesterase Type 5 (PDE5) Inhibitor market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Sildenafil
Tadalafil
Avanafil
Vardenafil

Segment by Application
Hospital
Retail Pharmacy
Online Pharmacies
Other

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Eli Lilly
Pfizer
Bayer
Novartis AG
Merck
GlaxoSmithKline plc
Roche
AstraZeneca
BaiYunShan General Factory
SK Chemicals
Teva Pharma
Dong-A ST
Metuchen Pharma
Seoul Pharma
Vectura Group